Premium
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC... Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. Show more
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of...
- Late-breaker presentation to feature data from VANTAGE study evaluating volixibat in primary biliary cholangitis Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present...
Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted breakthrough therapy designation for treatment of cholestatic pruritus in...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 8, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and...
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2024 financial results on November 12, 2024. Mirum will also host a conference call to discuss the...
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.55 | -5.83791208791 | 43.68 | 43.968 | 40.03 | 437147 | 41.95181764 | CS |
| 4 | -2.79 | -6.35245901639 | 43.92 | 47.08 | 40.03 | 364995 | 43.84073088 | CS |
| 12 | 1.94 | 4.95024240878 | 39.19 | 48.89 | 37.51 | 359970 | 41.92274247 | CS |
| 26 | 11.13 | 37.1 | 30 | 48.89 | 28.56 | 495734 | 39.72739746 | CS |
| 52 | 11.43 | 38.4848484848 | 29.7 | 48.89 | 23.14 | 538071 | 33.01577365 | CS |
| 156 | 26.22 | 175.855130785 | 14.91 | 48.89 | 14.63 | 440063 | 28.43221601 | CS |
| 260 | 17.91 | 77.1317829457 | 23.22 | 48.89 | 9.14 | 314135 | 26.78077429 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
